Biocytogen Keeps Share Capital Unchanged in July 2026, Confirms Public Float Compliance

Bulletin Express08-05

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. filed its monthly return for the period ended 31 July 2026, showing no movements in either authorised or issued share capital across its H and A share classes.

Authorised/Registered Share Capital • H shares: 110.78 million shares at RMB 1 par value, unchanged. • A shares: 336.12 million shares at RMB 1 par value, unchanged. • Total authorised share capital remained at RMB 446.90 million.

Issued Shares and Treasury Position • H shares issued: 110.78 million; treasury shares: zero. • A shares issued: 336.12 million; treasury shares: zero. • No new share issuance, repurchase, or cancellation occurred during the month.

Public Float • The company confirmed compliance with the Hong Kong Exchange’s 5 % minimum public-float requirement for H shares.

Corporate Actions • No outstanding or newly granted share options, warrants, convertible securities, or other equity arrangements were reported.

The filing indicates a stable capital structure for Biocytogen during July 2026, with full adherence to listing rules and no dilution or treasury movements. Joint Company Secretary Wang Yongliang submitted the return on 5 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158790095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158790095","market":"hk","top_or_hot":-1,"title":"Biocytogen Keeps Share Capital Unchanged in July 2026, Confirms Public Float Compliance","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. filed its monthly return for the period ended 31 July 2026, showing no movements in either authorised or issued share capital across its H and A share classes.</p>\n<p>Authorised/Registered Share Capital  \n• H shares: 110.78 million shares at RMB 1 par value, unchanged.  \n• A shares: 336.12 million shares at RMB 1 par value, unchanged.  \n• Total authorised share capital remained at RMB 446.90 million.</p>\n<p>Issued Shares and Treasury Position  \n• H shares issued: 110.78 million; treasury shares: zero.  \n• A shares issued: 336.12 million; treasury shares: zero.  \n• No new share issuance, repurchase, or cancellation occurred during the month.</p>\n<p>Public Float  \n• The company confirmed compliance with the Hong Kong Exchange’s 5 % minimum public-float requirement for H shares.</p>\n<p>Corporate Actions  \n• No outstanding or newly granted share options, warrants, convertible securities, or other equity arrangements were reported.</p>\n<p>The filing indicates a stable capital structure for Biocytogen during July 2026, with full adherence to listing rules and no dilution or treasury movements. Joint Company Secretary Wang Yongliang submitted the return on 5 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Keeps Share Capital Unchanged in July 2026, Confirms Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Keeps Share Capital Unchanged in July 2026, Confirms Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-05 10:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. filed its monthly return for the period ended 31 July 2026, showing no movements in either authorised or issued share capital across its H and A share classes.</p>\n<p>Authorised/Registered Share Capital  \n• H shares: 110.78 million shares at RMB 1 par value, unchanged.  \n• A shares: 336.12 million shares at RMB 1 par value, unchanged.  \n• Total authorised share capital remained at RMB 446.90 million.</p>\n<p>Issued Shares and Treasury Position  \n• H shares issued: 110.78 million; treasury shares: zero.  \n• A shares issued: 336.12 million; treasury shares: zero.  \n• No new share issuance, repurchase, or cancellation occurred during the month.</p>\n<p>Public Float  \n• The company confirmed compliance with the Hong Kong Exchange’s 5 % minimum public-float requirement for H shares.</p>\n<p>Corporate Actions  \n• No outstanding or newly granted share options, warrants, convertible securities, or other equity arrangements were reported.</p>\n<p>The filing indicates a stable capital structure for Biocytogen during July 2026, with full adherence to listing rules and no dilution or treasury movements. Joint Company Secretary Wang Yongliang submitted the return on 5 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1158790095","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158790095","pubTimestamp":1785896734,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. filed its monthly return for the period ended 31 July 2026, showing no movements in either authorised or issued share capital across its H and A share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"Biocytogen 2026 年 7 月股本保持不变，确认符合公开发行要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. filed its monthly return for the period ended 31 July 2026, showing no movements in either authorised or issued share capital across its H and A share classes.\nAuthorised/Registered Share Capital  \n• H shares: 110.78 million shares at RMB 1 par value, unchanged.  \n• A shares: 336.12 million shares at RMB 1 par value, unchanged.  \n• Total authorised share capital remained at RMB 446.90 million.\nIssued Shares and Treasury Position  \n• H shares issued: 110.78 million; treasury shares: zero.  \n• A shares issued: 336.12 million; treasury shares: zero.  \n• No new share issuance, repurchase, or cancellation occurred during the month.\nPublic Float  \n• The company confirmed compliance with the Hong Kong Exchange’s 5 % minimum public-float requirement for H shares.\nCorporate Actions  \n• No outstanding or newly granted share options, warrants, convertible securities, or other equity arrangements were reported.\nThe filing indicates a stable capital structure for Biocytogen during July 2026, with full adherence to listing rules and no dilution or treasury movements. Joint Company Secretary Wang Yongliang submitted the return on 5 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158790095","isCrawlerRequest":true}